Personalized mRNA Melanoma Vaccine Reduces Recurrence Risk 42% Personalized mRNA Melanoma Vaccine Reduces Recurrence Risk 42% By Mitchell Landsberg on October 26, 2026 A phase 3 trial shows a personalized mRNA vaccine cut melanoma recurrence or death risk by 42% when added to pembrolizumab.